Clinical Trials Browser

Phase 1/2 × Trastuzumab × Gastrointestinal × Clear all

NCT07040059 2026-04-17

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 1/2 Terminated

Gastrointestinal

HER 2 Positive Gastric Cancer

NCT06324357 2026-04-15

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT05555251 2024-12-16

CONTRAST

Phase 1/2 Terminated

BreastGastrointestinal

HER2-positive Breast Cancer

NCT05207722 2024-12-12

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Phase 1/2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT05640830 2024-11-26

TREAZURE

Phase 1/2 Recruiting

Gastrointestinal

HER2-positive Advanced Gastric Cancer

NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Phase 1/2 Recruiting

Gastrointestinal

Metastatic HER2 Positive Gastroesophageal Junction Cancer

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1/2 Terminated

2 enrolled 9 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT04888663 2021-05-21

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Phase 1/2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02901301 2021-04-06

Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer

Phase 1/2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT02120911 2020-07-01

TRAP

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT02318901 2019-10-21

PembroMab

Phase 1/2 Terminated

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00923299 2019-04-16

THERAPY

Phase 1/2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02030561 2016-06-22

NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

Phase 1/2 Unknown

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT02805829 2016-06-22

Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer

Phase 1/2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT01746771 2016-03-03

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

Phase 1/2 Completed

Gastrointestinal

HER-2 Positive Advanced Gastric Cancer